Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line WT1-targeted dendritic cell vaccination for malignant pleural mesothelioma
2024-517970-35-00Phase 2Completed
- Sponsor
- Antwerp University Hospital
- Start
- Nov 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1 LAMP mRNA dendritic cell vaccine in pleural mesothelioma, sponsored by Antwerp University Hospital. Primary endpoints: Safety of WT1 LAMP mRNA DC vaccination and Feasibility of WT1 LAMP mRNA DC vaccination combined with chemotherapy. Started Nov 2024; status: completed.
02
Drugs
WT1 LAMP mRNA dendritic cell vaccine
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2024-517970-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517970-35-00.